Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

FMT+ QL1706+ Bevacizumab+ Xelox som førstelinjebehandling for avanceret MSS-typen typekræft med levermetastase

22. september 2026 opdateret af: Hua Jiang

Fækal mikrobiota-transplantation kombineret med QL1706, bevacizumab og Xelox som førstelinjebehandling til avanceret MSS-typekræft med levermetastase: studieprotokol for en prospektiv, multi-centre, enkeltarm fase II-udforskningsforsøg

The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 30 patients with advanced colorectal cancer patients with liver metastasis who have not received prior treatment. This study plans to reconstruct intestinal microecology through fecal microbiota transplantation (FMT), and combine with QL1706+Bevacizumab+XELOX to enhance the anti-tumor immune effect at the same time, thereby improving the prognosis of colorectal cancer patients with liver metastasis.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is a prospective, single-arm, multi-center, exploratory clinical study. Patients with previously untreated, newly diagnosed advanced colorectal cancer with liver metastasis, who could be diagnosed by histological or cytological means, ECOG PS 0-1, excluded Ras, Raf wild type left colon/rectum, excluded dMMR/MSI-H. Eligible subjects who met the inclusion criteria were screened and signed informed consent.

FMT was performed 2 days after treatment with bevacizumab, and chemotherapy. QL1706, bevacizumab, and chemotherapy (XELOX) were administered every 3 weeks according to the patient's body surface area. A total of 6 cycles were performed. Subsequent maintenance therapy was at the discretion of the investigator.

RECIST v1.1 was used for tumor evaluation every 6 weeks during treatment. NCI-CTCAE 5.0 was used for safety assessment every 3 weeks. Adverse events were recorded throughout the study to 90 days after the end of treatment. Treatment continues until disease progression, subject withdraws informed consent, loss of follow-up, or death. Patients should provide 10ml whole blood samples and fecal samples at baseline, after two cycles of treatment, after four cycles of treatment, before maintenance treatment for the detection of efficacy prediction markers (each cycle is 21 days).

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

30

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Changzhou, Kina
        • Rekruttering
        • The Second People's Hospital of Changzhou
        • Kontakt:
          • Hua Jiang MD
          • Telefonnummer: +86-18015852711

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Histological or cytological confirmed advanced colorectal cancer with liver metastasis.
  2. Signed written informed consent.
  3. Have not received anti-tumor treatment.
  4. According to the investigators assessment, at least one measurable target lesion defined by RECIST v1.1.
  5. Patients of both sexes, aged ≥18 years and ≤75 years.
  6. ECOG PS 0-1;
  7. Expected survival time ≥ 3 months;
  8. Have adequate organ and bone marrow function, laboratory examination within 7 days prior to enrollment meets the following requirements, as follows:

1) Blood routine: ANC ≥ 1.5 × 10^9/L, Platelet count ≥ 100 × 10^9/L, HGB ≥100 g/L (no blood transfusion or erythropoietin dependence within 14 days); 2) Liver function: TBIL ≤1.5 x ULN; ALT/AST ≤ 5 x ULN; ALP ≤5×ULN; 3) Renal function: Cr ≤1.5×ULN, or creatinine clearance ≥50 mL/min: Urine routine results showed urinary protein < 2+; 4) Coagulation function: INR or PT ≤1.5 x ULN. 9.For female subjects of reproductive age, a urine or serum pregnancy test should be performed and the result is negative 3 days prior to receiving the initial study drug administration.

10. For women of childbearing potential (WOCBP): agreement to refrain from heterosexual intercourse or use contraception.

11. For men: agreement to refrain from heterosexual intercourse or use a condom, and agreement to refrain from donating sperm.

Exclusion Criteria:

  1. Suffered from other malignancies in the past 5 years, excluding cured basal cell carcinoma of the skin, cervical carcinoma in situ and papillary thyroid carcinoma.
  2. Patients requiring elective surgery during the trial.
  3. Patients who cannot take oral drugs, or have conditions that the investigator determines to significantly affect gastrointestinal absorption, such as chronic diarrhea, intestinal obstruction, etc., and are not suitable for treatment.
  4. Patients during pregnancy (positive pregnancy test) or lactation.
  5. Central nervous system metastasis or meningeal metastasis.
  6. Uncontrollable bone metastasis, or patients at risk of fracture, requiring surgery, local radiation therapy.
  7. Patients with active infection requiring systemic anti-infection treatment.
  8. Patients with a history of immunodeficiency, including those who are positive for HIV antibody tests.
  9. Patients with known, active autoimmune diseases.
  10. Patients with uncontrolled active hepatitis B, patients with hepatitis C virus infection (HCV antibody positive).
  11. A history of severe cardiovascular and cerebrovascular diseases, including but not limited to: severe arrhythmia, acute coronary syndrome within 6 months, congestive heart failure, aortic dissection, stroke, and T IA history.
  12. Severe bleeding events occur within half a year, or high bleeding risk factors such as active digestive tract ulcers and esophageal and gastric varices due to liver cirrhosis.
  13. Patients with diabetes who cannot be stably controlled by drugs (including insulin).
  14. Mental or language disorders that prevent communication with the patient;
  15. Patients participating in another clinical trial.
  16. MSI-H/ d MMR without immunotherapy; left colorectum of Ras, Raf wild-type.
  17. The investigator believes that the subject has other serious systemic diseases or other conditions that make him unsuitable for participation in this trial.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Fmt+ql1706+bevacizumab+xelox

Participants will receive FMT combined with QL1706+Bevacizumab+XELOX for 6 cycles. If there is no progression of the disease after 6 cycles of the first-line treatment, then patients will enter the maintenance treatment stage. The therapy of maintenance treatment stage was at the discretion of the investigator.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Objective Response Rate (ORR)
Tidsramme: up to 24 months

Objective response rate will be assessed by investigators.

up to 24 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Median Progression-Free Survival (mPFS)
Tidsramme: up to 24 months

Observation for mPFS will be recorded until the end of follow-up after the start of 1st cycle of treatment.

up to 24 months
Median Overall Survival (mOS)
Tidsramme: up to 24 months

The time from the first treatment to death from any cause.

up to 24 months
6-Months Progression-Free Survival Rate (6month-PFS)
Tidsramme: up to 6 months

The proportion of patients whose disease did not progress 6 months after treatment

up to 6 months
12-Months Progression-Free Survival Rate (12month-PFS)
Tidsramme: up to 12 months

The proportion of patients whose disease did not progress 12 months after treatment

up to 12 months
18-Months Progression-Free Survival Rate (18month-PFS)
Tidsramme: up to 18 months

The proportion of patients whose disease did not progress 18 months after treatment

up to 18 months
6-Months overall survival rate(6-Months-OS Rate)
Tidsramme: up to 6 months

The proportion of patients who have not died after 6-Months of treatment

up to 6 months
12-Months overall survival rate(12-Months-OS Rate)
Tidsramme: up to 12 months

The proportion of patients whose disease did not progress 12 months after treatment

up to 12 months
18-Months overall survival rate(18-Monthsr-OS Rate)
Tidsramme: up to 18 months

The proportion of patients who have not died after 18 months of treatment

up to 18 months
Objective Response Rate (ORR) of liver metastases
Tidsramme: up to 24 months

Objective response rate will be assessed by investigators.

up to 24 months
Disease Control Rate (DCR)
Tidsramme: up to 24 months

The proportion of patients whose tumors achieve a response (CR+PR) and stable disease (SD) after treatment for the minimum duration required.

up to 24 months
Surgical conversion rate
Tidsramme: up to 24 months

Proportion of inoperable patients converted to operable.

up to 24 months
Incidence of Adverse events (AEs)
Tidsramme: up to 24 months

Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).

up to 24 months
Quality of Life (QoL)
Tidsramme: up to 24 months

QoL(quality of life) will be evaluated by EORTC-QLQ-C30.The total score ranges from 0 to 60, with higher scores indicating better quality of life

up to 24 months
The Diversity of Fecal Microbiota
Tidsramme: up to 24 months

This will be detected by 16s rRNA sequencing or metagenomes.

up to 24 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

17. april 2025

Primær færdiggørelse (Anslået)

1. februar 2027

Studieafslutning (Anslået)

1. februar 2027

Datoer for studieregistrering

Først indsendt

25. januar 2025

Først indsendt, der opfyldte QC-kriterier

25. januar 2025

Først opslået (Faktiske)

30. januar 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

24. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • [2025]YLJSA057-01

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .